## SAFETY (preliminary)

- In general, overall adverse events appear balanced between treatment arms.
- No patients in either treatment arm had an adverse event of heart failure reported.
- There were 3 deaths within 30 days of the last day of study drug on CPOP-R arm. Two of the events were attributed to study treatment (pneumonia concurrent with neutropenia and non-cardiogenic pulmonary edema concurrent with non-neutropenic infection). No deaths within 30 days of the last dose of study drug were reported in the CHOP-R arm.
- Overall rates of infection were similar in the CPOP-R and CHOP-R arms (23% vs. 28%, respectively).
- Transient blue or gray discoloration of skin and blue or green discoloration of nails have been reported.
- No instances of serious or significant hepatic or renal damage related to study therapy have been reported in either treatment arm.

### Summary of Adverse Events

<table>
<thead>
<tr>
<th>Category</th>
<th>CPOP-R</th>
<th>CHOP-R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3/4 neutropenia</td>
<td>3 (8%)</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>Grade 3/4 leukopenia</td>
<td>7 (18%)</td>
<td>6 (15%)</td>
</tr>
<tr>
<td>Grade 3/4 anemia</td>
<td>5 (13%)</td>
<td>5 (13%)</td>
</tr>
<tr>
<td>Grade 3/4 infection</td>
<td>5 (13%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (5%)</td>
<td>3 (8%)</td>
</tr>
</tbody>
</table>

### TREATMENT RESPONSES

<table>
<thead>
<tr>
<th>Category</th>
<th>CPOP-R</th>
<th>CHOP-R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response Rate (CR+PR) at the cycle 4 assessment</td>
<td>32%</td>
<td>32%</td>
</tr>
</tbody>
</table>

## SUMMARY and CONCLUSIONS

- Based on this preliminary analysis, we conclude that for 1st line therapy of patients with DLBCL, CPOP-R has similar activity to CHOP-R with no more toxicity.
- Cardiac safety, based on reporting of adverse events and LVEF assessment, was similar between treatment arms.
- Further follow-up is required.

### References


### Notes

1. CR: Complete Response
2. PR: Partial Response
3. CR+PR: Complete Response + Partial Response
4. LVEF: Left Ventricular Ejection Fraction
5. CTC: Common Toxicity Criteria
6. CTC grade 3-4 uncontrolled intercurrent infection
7. CTC grade 4-5 uncontrolled intercurrent infection
8. AE: Adverse Event